Apnimed Inc (APMD) Stock Price, Quote & News

Company Profile

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Industry: Biotechnology

Sector: Healthcare

Phone: (617) 500-8880

Website: apnimed.com

Address:

39 John F. Kennedy Street, 4th Floor, Cambridge, United States

malibu_rum67 Aug. 17 at 5:00 PM

$IXHL $APMD … Eeny Meeny Miny Moe🎤🎵🎶!!! Pick The Best One Of Them All!!! Who’s Your Bet😈!!! Trade With Caution ⚠️

0 · Reply

malibu_rum67 Aug. 17 at 4:48 PM

$IXHL $APMD … Trade CAREFULLY!!! Once It Said That One Is Better Than The Other, Things Can Happen Very Quickly!!! Watch Your Trade Like A Hawk!!! Be Aware Of The Timelines … Points Of Comparison Is Coming Very 🔜 !!! There’s A Lot Of Room In Liquidity Here!!! DON’T BE THE VICTIM!!!

0 · Reply

OldManGrumble Aug. 14 at 5:39 PM

$APMD 👍

0 · Reply

TraderGOAT Aug. 13 at 11:12 PM

$APMD Looking good today 👌. Up over 76% so far. 200% more to go to PDUFA in February 2027🤙

0 · Reply

RogueFF7 Aug. 12 at 12:09 PM

$APMD There’s always profit taking.

1 · Reply

stockro1 Aug. 11 at 12:28 PM

The $APMD MC is overwhelmingly positive for $IXHL The marker has been set, whether that is for acquisition or simply market target. Currently at ~$40M. Yep. Let’s go.

1 · Reply

Neurogirl Aug. 11 at 11:10 AM

$APMD $IXHL it’s good to have more then one medication to treat a condition . They are not our nemesis . Bad management is our issue not apnimed

1 · Reply

Neurogirl Aug. 11 at 11:08 AM

$APMD $IXHL what is the point of this? APMD MC is 1 B . It has extremely low volume and swings several dollars a day. It’s PDUFA is Feb 2027. Why are you posting this? It’s 27.88 a share. These are apples and oranges . If anything it may help

1 · Reply

SeamuSMingluS Aug. 11 at 9:02 AM

$IXHL $APMD Mate all due respect use the data from RePosa. Getting Chatgtp to pump out a pile of shit making comparisons to Apnimed using a 10 person 7 day trial 🤣🤣🤣🤣🤣🤣 Use RePOSA results Overlay Acetazolamide monotherapy historical data.... The trial was 13.9 and 14.7% > than 50% reduction on a 28day trial. With @ 40% getting 33% or more . Might explain the Valuation gap. Pathways

0 · Reply

SurfyKnagg Aug. 11 at 8:27 AM

$IXHL $APMD Even the market knows! 🤣

1 · Reply

Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

2026-07-31T16:15:53.000Z - 18 days ago

Apnimed opens at $22.00, IPO priced at $16.00

2026-07-31T11:05:54.000Z - 19 days ago

Apnimed 12M share IPO priced at $16.00

Jul 27, 2026, 8:16 AM EDT - 23 days ago

Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO

Jul 10, 2026, 7:04 PM EDT - 5 weeks ago

Sleep apnea pill maker Apnimed files for US IPO as biotech market revives

Jul 10, 2026, 4:15 PM EDT - 5 weeks ago

Apnimed IPO Registration Document (S-1)

malibu_rum67 Aug. 17 at 5:00 PM

$IXHL $APMD … Eeny Meeny Miny Moe🎤🎵🎶!!! Pick The Best One Of Them All!!! Who’s Your Bet😈!!! Trade With Caution ⚠️

0 · Reply

malibu_rum67 Aug. 17 at 4:48 PM

0 · Reply

OldManGrumble Aug. 14 at 5:39 PM

$APMD 👍

0 · Reply

TraderGOAT Aug. 13 at 11:12 PM

$APMD Looking good today 👌. Up over 76% so far. 200% more to go to PDUFA in February 2027🤙

0 · Reply

RogueFF7 Aug. 12 at 12:09 PM

$APMD There’s always profit taking.

1 · Reply

stockro1 Aug. 11 at 12:28 PM

The $APMD MC is overwhelmingly positive for $IXHL The marker has been set, whether that is for acquisition or simply market target. Currently at ~$40M. Yep. Let’s go.

1 · Reply

Neurogirl Aug. 11 at 11:10 AM

$APMD $IXHL it’s good to have more then one medication to treat a condition . They are not our nemesis . Bad management is our issue not apnimed

1 · Reply

Neurogirl Aug. 11 at 11:08 AM

1 · Reply

SeamuSMingluS Aug. 11 at 9:02 AM

0 · Reply

SurfyKnagg Aug. 11 at 8:27 AM

$IXHL $APMD Even the market knows! 🤣

1 · Reply

SurfyKnagg Aug. 11 at 8:08 AM

$IXHL vs $APMD Glaring valuation gap. Market values Apnimed at $1B+ vs $37 M for IXHL, but P2 data shows 42X leading on core endpoints from P2 data alone: • Mean AHI Reduction: ~50.7% vs ~44-47% • ODI Drop: ~59.7% vs ~40-45% • Tolerability: Lower dropouts than placebo vs ~21% P3 dropouts for AD109 (SNRI side effects as we know, dry mouth, INSOMNIA 🤪 ) DReAMzz is a P2 dose-optimization study. Replicating RePOSA P2 numbers like found from the low dose ALONE (as simple as that) locks in a superior candidate for Phase 3. We literally have a more tolerable drug right now, but management think there could be a slightly better one out there. Plus, 14 P3 sites are being qualified NOW for a seamless crossover, with Fast Track already secured. IHL-42X offers better numbers and restorative sleep without central nervous system disruption. The market cap is lagging the science big style. PSX-001.... IHL-675A.... Any reason not to be >>>>>

0 · Reply

Petalotapus Aug. 10 at 7:33 PM

$APMD This stock is clearly a no brainer. 30 million Sleep Apneans diagnosed and already on their stupid 'Life Support Machines' every night for the rest of their lives. They have to clean them properly every day or risk getting bacterial lung infection or better known as pneumonia. Medical community speculates another 50 million undiagnosed. Then there is the 'Ace Card'. Snoring is also put to sleep, mind the pun. Obviously going to take a few months to gain traction but who cares. FDA has fast tracked this pill and will respond by by Feb. 28th. U.S. sales will be one thing, but sales abroad will send this medicine into the stratosphere. I believe it will be bought be large pharma company within a year. I am going large and long. This will definitely be a 'Told You So'.

0 · Reply

SeamuSMingluS Aug. 10 at 11:11 AM

$APMD Why would folks come and parasite themselves onto the Apnimed page Same space 🤣🤣🤣🤣 Thats a good one Hello Sir i am calling from Fubai i have many mechanisms narratives resonating with my low dose synergistic effect.....but wait Sir we are still testing more synergies with combinations of compounds.

0 · Reply

SurfyKnagg Aug. 10 at 10:54 AM

$APMD $IXHL Looks like apnimed currently stabalised around $25- $27 a current $1.12B MC. Cant wait for $90 / Share for my IXHL shares post 42x P3 Not to mention PSX-001 $APMD board dead $IXHL we got this team

3 · Reply

ACInvestorBlog Aug. 5 at 2:59 PM

Same broader OSA treatment space. Completely different valuations. Vivos Therapeutics $VVOS FDA-cleared oral appliances for sleep apnea. Market cap: $5 million. Apnimed $APMD Oral once-nightly pill for sleep apnea (just IPOed). Market cap: $1 billion. One company is valued at roughly 150–200x the other while both target the same massive patient population. Wild how different the market treats devices vs. a potential first-in-class pill. 🤯

1 · Reply

OldManGrumble Aug. 4 at 8:55 PM

$APMD

0 · Reply

Acropolis17 Aug. 4 at 8:35 PM

$APMD up to 80 million Americans with OSA, most people hate CPAP, subtract OSA due to weight, probably still 40 million possible patients. Love this stock

1 · Reply

SeamuSMingluS Aug. 4 at 4:37 AM

$APMD Congratulations to holders of Apnimed stock. Can see this stock having excellent growth potential over 12months. The need for an OSA pharmaceutical treatment is huge.

0 · Reply

stockro1 Aug. 4 at 3:56 AM

$IXHL $35M $APMD $1BILL Yep, we have space to move alright.

0 · Reply

topstockalerts Aug. 4 at 12:46 AM

Apnimed completed its initial public offering, raising approximately $220.8 million in gross proceeds by selling 13.8 million shares at $16.00 per share, including the full exercise of the underwriters’ over-allotment option. The shares began trading on the Nasdaq Global Select Market on July 31 under the ticker APMD, marking one of the latest biotech IPOs as investor interest in the sector gradually improves. The Cambridge, Massachusetts-based clinical-stage biopharmaceutical company is focused on developing AD109, an oral treatment for obstructive sleep apnea (OSA) across mild, moderate, and severe cases. The therapy has successfully completed two Phase 3 clinical trials, positioning the company for a potential commercial launch if approved. Apnimed said its New Drug Application (NDA) has been accepted by the FDA and assigned a PDUFA target action date of February 28, 2027. $APMD $NASDAQ

0 · Reply

theflynews Aug. 3 at 3:37 PM

Opening Day: Soft debuts for Jersey Mike’s, Reformation - $APMD - https://thefly.com/APMD

0 · Reply

IPOtweet Aug. 3 at 10:27 AM

IPO Winners & Losers: Biotech Soars, Jersey Mike's Misses, and SpaceX Faces the Lockup $JMKE $SPCX $APMD $IPO #IPO https://zpr.io/ks3wUsRe

0 · Reply

Market Cap	905.64M
Revenue (ttm)	38.47M
Net Income (ttm)	-932,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2.42%
Debt to Equity Ratio	0.00

Volume	347,900
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	27.82M
Stochastic %K	73%
Beta	N/A
Analysts	Strong Buy
Price Target	N/A